Meta-Analysis of the use of low-dose beta-adrenergic blocking therapy in tdiopathic or ischemic dilated cardiomyopathy

American Journal of Cardiology

Volumn 77, Issue 14, 1996, Pages 1247-1250

  Zarembski, Dawn G ^a   Nolan Jr , Paul E ^a   Slack, Marion K ^a   Lui, Charles Y ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; ENOXIMONE; METOPROLOL; NEBIVOLOL;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART DILATATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARDIOMYOPATHY, DILATED; HUMANS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0029973510     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00175-0     Document Type: Article

References (29)

1. Francis GS, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. The neurohormonal axis in congestive heart failure. Ann Intern Med 1984;101:370-377.
2. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-1666.
3. Curtiss C, Cohn NJ, Vrobel T. Role of the renin angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-770.
4. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
5. Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66:843-848.
6. Das Gupta P, Broadhurst P, Raferty EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-1123.
7. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta-blockade in congestive cardiomyopathy. Lancet 1991;1:490-492.
8. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-490.
9. Waagstein F, Caidahl K, Wallentin I, Berh C, Hjalmarson A. Long-term betablockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563.
10. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-133.
11. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
12. CIBIS Investigators. A randomized trial of beta-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994;90:1765-1773.
13. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546.
14. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholomew M. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-475.
15. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connoll JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee PL, Bristow MR. Longterm beta-blockade vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind randomized study of bucindolol versus placebo. Am J Med 1990;88:223-229.
16. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603-607.
17. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
18. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, One J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642.
19. Metra M, Nardi M, Giubini R, Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
20. Wisenbaugh T, Katz I, Davis I, Essop R, Skoularigis J, Middelmost S, Rothisberger C, Skudicky D, Sareli P. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100.
21. Waagstein F, Bristow M, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilben EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
22. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
23. Wolf FM. Meta-analysis: Quantitative Methods for Researćh Synthesìs. Beverly Hills, Calif: Sage Publications; 1986.
24. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in paatients with severe chronic heart failure. Circulation 1995;92: 1499-1506.
25. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow M. Assessment of beta-adrenergic receptor pathway in the intact human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986;74:1290-1302.
26. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87(suppl VI): VI-17-VI-23.
27. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985;17:291-306.
28. Bristow MR, Ginsburg R, Minobe W, Cubicotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-211.
29. Uretsky BF, Jessup M, Konstam MA, Dec W, Leier CV, Benotti J, Murali S, Herrman HC, Sandberg JA, for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation 1990;82:774-780.